Page 2275 - Hematology_ Basic Principles and Practice ( PDFDrive )

2022 Part XII Hemostasis and Thrombosis

6. DiMichele D: Inhibitor development in haemophilia B: an orphan 22. Plug I, van der Bom JG, Peters M, et al: Mortality and causes of death
disease in need of attention. Br J Haematol 138:305, 2007. in patients with hemophilia, 1992-2001: a prospective cohort study.
7. Rogaev EI, Grigorenko AP, Faskhutdinova G, et al: Genotype analysis J Thromb Haemost 4:510, 2006.
identifies the cause of the “royal disease. Science 326:817, 2009. 23. Mannucci PM, Aberg M, Nilsson IM, et al: Mechanism of plasminogen
8. Mazurier C: Von Willebrand disease masquerading as haemophilia A. activator and factor FVIII increase after vasoactive drugs. Br J Haematol
Thromb Haemost 67:391, 1992. 30:81, 1975.
9. Ljung R, Chambost H, Stain A-M, et al: Haemophilia in the first years 24. Van Creveld S: Prophylaxis of joint hemorrhages in hemophilia. Acta
of life. Haemophilia 14:188, 2008. Haematol 45:120, 1971.
10. Dauty M, Sigaud M, Trossaërt M, et al: Iliopsoas hematoma in patients 25. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al: Prophylaxis versus
with hemophilia: a single-center study. Joint Bone Spine 74:179, 2007. episodic treatment to prevent joint disease in boys with severe hemo-
11. van Dijk K, Fischer K, van der Bom JG, et al: Variability in clini- philia. N Engl J Med 357:535, 2007.
cal phenotype of severe haemophilia: the role of the first joint bleed. 26. Gouw SC, van der Bom JG, Auerswald G, et al: Recombinant versus
Haemophilia 11:438, 2005. plasma-derived factor VIII products and the development of inhibitors
12. Valentino LA: Blood-induced joint disease: the pathophysiology in previously untreated patients with severe hemophilia A: the CANAL
of hemophilic arthropathy. Journal of thrombosis and haemostasis. cohort study. Blood 109:4693, 2007.
J Thromb Haemost 8:1895, 2010. 27. Feldman BM, Pai M, Rivard GE, et al: Tailored prophylaxis in severe
13. Blanchette VS, Key NS, Ljung LR, et al: Definitions in hemophilia: hemophilia A: interim results from the first 5 years of the Canadian
communication from the SSC of the ISTH. J Thromb Haemost 12:1935, hemophilia primary prophylaxis study. J Thromb Haemost 4:1228, 2006.
2014. 28. Liang TJ, Ghany MG: Therapy of hepatitis C — back to the future. N
14. Kulkarni R, Lusher JM: Intracranial and extracranial hemorrhages in Engl J Med 370:2043, 2014.
newborns with hemophilia: a review of the literature. J Pediatr Hematol 29. Warrier I, Ewenstein BM, Koerper MA, et al: Factor IX inhibitors and
Oncol 21:289, 1999. anaphylaxis in hemophilia B. Haemophilia 3:131, 1997.
15. Shapiro AD, Donfield SM, Lynn HS, et al: Defining the impact of 30. Recht M, Pollmann H, Tagliaferri A, et al: A retrospective study to
hemophilia: the academic achievement in children with hemophilia describe the incidence of moderate to severe allergic reactions to factor
study. Pediatrics 108:E105, 2001. IX in subjects with haemophilia B. Haemophilia 17:494, 2011.
16. Ragni MV, Lusher JM, Koerper MA, et al: Safety and immunogenic- 31. Sehgal A, Barros S, Ivanciu L, et al: An RNAi therapeutic targeting anti-
ity of subcutaneous hepatitis A vaccine in children with haemophilia. thrombin to rebalance the coagulation system and promote hemostasis
Haemophilia 6:98, 2000. in hemophilia. Nat Med 21:492, 2015.
17. Johnson RE, Lawrence DN, Evatt BL, et al: Acquired immunodeficiency 32. Chowdary P, Lethagen S, Friedrich U, et al: Safety and pharmacokinetics
syndrome among patients attending hemophilia treatment centers and of anti-TFPI antibody (concizumab) in healthy volunteers and patients
mortality experience of hemophiliacs in the United States. Am J Epide- with hemophilia: a randomized first human dose trial. J Thromb Haemost
miol 121:797, 1985. 13:743, 2015.
18. Brettler DB, Alter HJ, Dienstag JL, et al: Prevalence of hepatitis C virus 33. Muto A, Yoshihashi K, Takeda M, et al: Anti-factor IXa/X bispecific
antibody in a cohort of hemophilia patients. Blood 76:254, 1990. antibody (ACE910): hemostatic potency against ongoing bleeds in a
19. Gouw SC, van der Bom JG, Ljung R, et al: Factor VIII products and hemophilia A model and the possibility of routine supplementation.
inhibitor development in severe hemophilia A. N Engl J Med 368:231, J Thromb Haemost 12:206, 2014.
2013. 34. Hough C, Lillicrap D: Gene therapy for hemophilia: an imperative to
20. Collins PW, Palmer BP, Chalmers EA, et al: Factor VIII brand and the succeed. J Thromb Haemost 3:1195, 2005.
incidence of factor VIII inhibitors in previously untreated UK children 35. Nathwani AC, Reiss UM, Tuddenham EG, et al: Long-term safety and
with severe hemophilia A, 2000-2011. Blood 124:3389, 2014. efficacy of factor IX gene therapy in hemophilia B. N Engl J Med
21. Calvez T, Chambost H, Claeyssens-Donadel S, et al: Recombinant factor 371:1994, 2014.
VIII products and inhibitor development in previously untreated boys
with severe hemophilia A. Blood 124:3398, 2014.